AD/PD - Advances in Science & Therapy

AD/PD™ 2026: Striving for a better future for all those affected by neurodegenerative diseases.
March 17-21 | Copenhagen, Denmark

[AD/PD - Advances in Science & Therapy @adpdnet]

And...that’s a wrap for #ADPD2026!✨

What an unforgettable few days in Copenhagen - filled with inspiring science, meaningful connections, and incredible moments shared across the global AD/PD™ community. 🧠🌍

Thank you to everyone who joined us - onsite and online - for being part of this journey.

🇪🇸 We can’t wait to see you next year in Barcelona for AD/PD™ 2027!

#Neuroscience #Alzheimers #Parkinsons #NeurodegenerativeDiseases #ADPDCommunity #SeeYouInBarcelona

[AD/PD - Advances in Science & Therapy @adpdnet]

⏱️ LAST CALL!
Join us tomorrow for a 60-minute live webinar exploring Taudia’s validated 5-plex laboratory-developed test (LDT) and its applications in clinical research.

📅 Tomorrow, 12 November 2026 at 16:00 CET
👉 REGISTER NOW: https://t.co/nHX7okmil0

Discover the science behind multi-analyte testing, explore Taudia’s SPLASH technology, and gain insights into assay validation and the role of 5-plex testing in AD research.

🚀 SECURE YOUR SPOT AND JOIN US LIVE TOMORROW!

This educational webinar is supported by #Taudia.

#AlzheimersDisease #Biomarkers #ClinicalResearch #Neuroscience #MedicalEducation #ADPDEducation #ADPDonUNLOK

[AD/PD - Advances in Science & Therapy @adpdnet]

One month left to register and save up to €150!

Register for AD/PD™ 2027 by December 9, 2026, to benefit from the early registration rates.
From 16–20 March 2027, Barcelona will bring together researchers and clinicians for five days of new science, open debate, and connections that continue well beyond the conference.

Register today: https://t.co/PWxnnZeZ3T

#ADPD2027 #AlzheimersResearch #ParkinsonsResearch #Neuroscience #Neurodegeneration

[AD/PD - Advances in Science & Therapy @adpdnet]

MEET THE EXPERTS!
Join three experts bringing complementary perspectives in assay development, clinical testing, and life sciences innovation:

👨‍⚕️ Paul Childress, PhD - Principal Investigator at Quantigen, with extensive experience in assay development, validation, and molecular and protein-based testing.

👨‍⚕️ Doug Rains - Chief Scientific Officer of Versiti Clinical Trials Solutions, with a background spanning oncology research, genetic testing, and biotechnology.

👨‍⚕️ Christopher Ng - Director of Operations at Taudia, specializing in proteomics, genomics, and bringing innovative life science products to clinical research.

Together, they’ll explore the science behind the validated AD 5-plex assay, Taudia’s SPLASH technology, and the role of multi-biomarker testing in clinical research.

📅 12 NOVEMBER AT 16:00 CET
👉 REGISTER NOW: https://t.co/O9BXwKHLRb

This educational webinar is supported by #Taudia.

#AlzheimersResearch #ClinicalTrials #AlzheimersDisease #Biomarkers #ClinicalResearch #Neuroscience #MedicalEducation #ADPDEducation #ADPDonUNLOK

[AD/PD - Advances in Science & Therapy @adpdnet]

🤝 Put your startup in front of specialists working in Alzheimer’s, Parkinson’s and related disorders.

The #ADPD2027 Startup Hub is an opportunity to share what you are building, gain expert perspectives and open the door to new opportunities.

🔗 Reserve your tabletop: https://t.co/PHycAQj83z

#Alzheimers #Parkinsons

[AD/PD - Advances in Science & Therapy @adpdnet]

"Having been in the field since 1988, it is quite extraordinary where we are today, and AD/PD has played a seminal role and will continue to do so." - Rhoda Au, Boston University, on AD/PD™ 2026. ✨

In Barcelona, Rhoda co-moderates the forum "AI → Impact: Can data-driven biology deliver real disease-modifying therapies?" with Randall Bateman.

🔗Join the conversation, 16–20 March 2027: https://t.co/pzGg56VgZy

#ADPD2027 #AlzheimersResearch #AI #Neuroscience

[AD/PD - Advances in Science & Therapy @adpdnet]

Why do so many researchers return to AD/PD™ every year?

✔️ A high-level scientific program focused on the latest research, with emphasis on overlaps between Alzheimer's, Parkinson's, and related disorders
✔️ A multidisciplinary mix of clinical investigators and basic scientists, established leaders and young talent
✔️ An atmosphere designed for interaction, exchange of ideas, and networking

Plenary speakers in Barcelona include Randall Bateman, Henrik Zetterberg, Brit Mollenhauer, Bradley Hyman, Rosa Rademakers, Costantino Iadecola, and Beth Stevens. ✨

📆Join us in Barcelona or online, 16–20 March 2027

Register: https://t.co/PWxnnZeZ3T

#ADPD2027 #AlzheimersResearch #ParkinsonsResearch #Neuroscience

[AD/PD - Advances in Science & Therapy @adpdnet]

🔬 The specialists deciding what moves forward in Alzheimer’s, Parkinson’s, and related disorders are at #ADPD2027.

Early-stage companies belong in that room. Get feedback and contacts that shape what your technology becomes.

🔗 Join the Startup Hub: https://t.co/PHycAQj83z

#Alzheimers #Parkinsons

[AD/PD - Advances in Science & Therapy @adpdnet]

"It is clear to me that we have entered a new and very positive phase, and that the speed of discovery and progress is higher than ever with quite innovative approaches." ✨

Henrik Zetterberg, University of Gothenburg, reflecting on AD/PD™ 2026 in Copenhagen.

In Barcelona, Henrik returns as a plenary speaker on fluid biomarkers for tau pathophysiology in Alzheimer's disease.

🔗Join us, save your seat today: https://t.co/pzGg56VgZy

#ADPD2027 #AlzheimersResearch #Biomarkers #Neuroscience

[AD/PD - Advances in Science & Therapy @adpdnet]

🧠 THE SCIENCE BEHIND AD 5-PLEX TESTING

Can five biomarkers provide a broader picture of Alzheimer's disease than a single biomarker?

Join Paul Childress, PhD, Doug Rains, and Christopher Ng for an expert-led discussion on multi-analyte blood-based testing, assay validation, and clinical research applications.

📅 Thursday, 12 November 2026
⏰ 16:00 CET
👉 REGISTER NOW: https://t.co/O9BXwKHLRb

This educational webinar is supported by #Taudia.

#AlzheimersDisease #Biomarkers #ClinicalResearch #Neuroscience #MedicalEducation #ADPDEducation #ADPDonUNLOK

[AD/PD - Advances in Science & Therapy @adpdnet]

Preparing a late-breaking abstract for #ADPD2027? A quick checklist before you submit:

✅ Data must be unpublished and not previously presented
✅ Title: max. 20 words, in UPPER CASE
✅ Abstract text: max. 280 words, structured as Objectives, Methods, Results, Conclusions
✅ The presenting author must be listed as first author
✅ Choose a Theme, Topic and Sub-Topic
✅ You're not submitted until you receive the confirmation email

AD/PD™ has no embargo policy, so you're free to share your work within your networks.

📅 Deadline: 18 November 2026, midnight CET

👉 https://t.co/UUme2Gt7Na

#ADPD2027 #AlzheimersResearch #ParkinsonsResearch #Neuroscience

[AD/PD - Advances in Science & Therapy @adpdnet]

Can't travel to Barcelona? You can still be part of AD/PD™ 2027.

As a hybrid conference, AD/PD™ 2027 lets you join live sessions online, alongside the in-person meeting in Barcelona, 16–20 March 2027.

With the Gold Track, you also keep access to session recordings, abstracts, e-posters, and the conference digital library for 6 months after the meeting.

📆 Early rates apply until 9 December 2026.
👉 https://t.co/PWxnnZeZ3T

#ADPD2027 #AlzheimersResearch #ParkinsonsResearch #Neuroscience

[AD/PD - Advances in Science & Therapy @adpdnet]

🧠 How do brain immune cells influence resilience and vulnerability in aging and disease?

The brain’s immune environment plays a crucial role in shaping health, aging, and neurodegeneration. Understanding how brain macrophages respond and adapt could reveal new insights into why some individuals maintain cognitive resilience while others become vulnerable to disease.

Join Beth Stevens, USA at AD/PD™ 2027 for the plenary session:
“How Do Brain Macrophages Shape Cognitive Resilience and Vulnerability in Aging and Disease?”

Find out more: https://t.co/hiFT4pfwzx

#Alzheimers #Parkinsons #Neurodegeneration #BrainResearch #Immunology #CognitiveHealth

[AD/PD - Advances in Science & Therapy @adpdnet]

📰Lipofuscin Ingredients Tie Development to Degeneration

"To scientists peering through a microscope, lipofuscin presents as a nuisance, interfering with immunohistochemical analysis. Could this poorly characterized, autofluorescent debris shine light on both neurodegenerative and neurodevelopmental disorders?

It accumulates steadily in neurons throughout life, and explosively in neuronal ceroid lipofuscinoses. These rare lysosomal storage diseases draw growing interest among scientists nowadays. 🔬

On May 3 in Acta Neuropathologica, Sreeganga Chandra of Yale University and colleagues report that in both NCLs and in normal aging, thioesterases—enzymes that remove fatty acid modifications from proteins—lose steam."

🔗 Continue reading: https://t.co/8XdEJAE4hg

[AD/PD - Advances in Science & Therapy @adpdnet]

Late-breaking abstract submission for #ADPD2027 is now open!

Have new, unpublished data that came in after the main deadline? This is your opportunity to share it with the global neurodegeneration community in Barcelona, 16 -20 March 2027.

Submissions are welcome across all 12 scientific themes, from β-amyloid diseases, tauopathies and α-Synucleinopathies to TDP43-related, vascular, prion, Huntington's and other neurodegenerative diseases.

📅 Deadline: 18 November 2026, midnight CET

📢 Notification to accepted authors: December 2026

Abstract topics: https://t.co/pzXZNC4IbF

#AlzheimersResearch #ParkinsonsResearch #Neuroscience #Neurodegeneration

[AD/PD - Advances in Science & Therapy @adpdnet]

Join Costantino Iadecola, USA at AD/PD™ 2027 in Barcelona for the plenary session:
“How the Neurovasculature Shapes Neurodegeneration: Toward a New Framework”

Discover emerging insights into the role of the neurovascular system in Alzheimer’s, Parkinson’s, and related disorders, and explore how a new understanding of brain–vascular interactions could shape future research and therapeutic strategies.

🌍 Be part of the global AD/PD™ community driving the next generation of discoveries.

Explore the AD/PD™ 2027 program 👉 https://t.co/hiFT4pfwzx

#Neuroscience #Alzheimers #Parkinsons #Neurodegeneration #BrainHealth

[AD/PD - Advances in Science & Therapy @adpdnet]

🧬 Can genetics unlock new paths to understanding and treating neurodegeneration?

From discovering disease-associated genes to identifying new opportunities for disease modification, explore the latest advances in genetics and their impact on the future of neurodegenerative research.

Join Rosa Rademakers, Belgium at AD/PD™ 2027 in Barcelona for the plenary session:
“Can Genetics Crack Neurodegeneration? From Discovery to Disease Modification?”

Learn more here👉 https://t.co/hiFT4pfwzx

#Neuroscience #Alzheimers #Parkinsons #Neurodegeneration #Genetics

[AD/PD - Advances in Science & Therapy @adpdnet]

📰GOLGA8—New FTLD-FET Gene with a Dinucleotide Expansion

"Rarely do scientists discover a new pathogenic mutation for a sporadic disease. Even less often do they find one that explains half the cases. Pinning disease on a dinucleotide expansion? That’s a new one.

And yet, in one fell swoop, Rosa Rademakers, University of Antwerp, Belgium, hit the trifecta. 🔬

In Nature Genetics March 12, a large team led by Rademakers reports that a CT dinucleotide repeat expansion in the GOLGA8A gene dramatically increases a person’s odds of having aFTLD-U, a rare subtype of frontotemporal dementia."

🔗 Continue reading: https://t.co/jGyCvcCTnu

[AD/PD - Advances in Science & Therapy @adpdnet]

#ADPD2027 Plenary Session Highlights

The Eric N. Birch Memorial Lecture brings together leading voices in neuroscience to explore major advances in neurodegenerative disease research.

Join Bradley Hyman, USA, at AD/PD™ 2027 in Barcelona as he discusses the molecular pathology of Lewy body diseases and the evolving understanding of disease mechanisms.

👉 Explore the plenary program: https://t.co/hiFT4pfwzx

#ADPD2027 #Neuroscience #LewyBodyDisease

[AD/PD - Advances in Science & Therapy @adpdnet]

Don’t miss your chance to be part of the AD/PD™ 2027 experience!🔬

As we gather the world’s top neuroscientists in Barcelona, the latest in #Alzheimers and #Parkinsons research will be front and center. From groundbreaking discoveries to pioneering treatments, you’ll be immersed in cutting-edge science and meet the leaders driving the field forward. 🧠

Join us, connect with peers, and push the boundaries of what’s possible.

🔗Secure your spot now at our early rates and be ready for what’s next. https://t.co/pzGg56VgZy

#dementia #endalz #neuroscience #neuroscientist #researcher #register

[AD/PD - Advances in Science & Therapy @adpdnet]

📰Sans Hypusine, Macrophages Flail in Brain and Other Tissues

"Resident macrophages dwell in virtually every tissue in the body. They maintain order, ward off threats, and make repairs.

They tailor their specific functions to each organ—for example, microglia in the brain prune synapses and gobble up protein aggregates, while so-called “dust cells” in the lungs remove inhaled debris, allergens, or pathogens.

According to a study published January 21 in Nature, these tissue specialists all rely on the same oddball molecular mechanism for their maturation and survival."

🔗 Continue reading: https://t.co/74DNdXmrFf